Loading…
INM
InMed Pharmaceuticals Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 457637700
$1.38-3.50%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $7.37M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.45
- ROE
- -112.65%
- Profit margin
- -172.17%
- Revenue growth
- —
- Beta
- 0.98
- 52-week high
- $2.50
- 52-week low
- $0.58
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
today you would have $1.58▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.38 | $1.06 | $4.74 | $8.32 | $40.40 | $655.00 | $1,645.00 | |
| P/S | 0.7x | — | 0.5x | 0.7x | 0.3x | 1.3x | 6.5x | — |
| P/B | 0.3x | 7.1x | 0.2x | 0.3x | 0.1x | 0.2x | 1.7x | 2.9x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CANFCan-Fite BioPharma Ltd. | $3.40 | — | 0.8x | — | -178.24% | $7.28M |
| NVNOenVVeno Medical Corp | $10.75 | — | 0.4x | — | -58.53% | $7.47M |
| CELZCreative Medical Technology Holdings Inc | $1.14 | — | 0.9x | — | -77.88% | $7.52M |
| CURXCuranex Pharmaceuticals Inc | $4.56 |
About the company
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
- 13
- Vancouver, Canada
Company description provided by Yahoo Finance.